FDA data Registry peer set 1 peer

Alternatives to aflibercept

1 same-class SPL records vs aflibercept - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Eylea

Anti-VEGF (Ophthalmic Injection) Prescription 1 alternative found

About aflibercept

AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.

Used for: AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.

1 Anti-VEGF (Ophthalmic Injection) peers (wide set)

Compare aflibercept vs ranibizumab side-by-side →

aflibercept vs ranibizumab · FAERS reaction fields

FAERS top-reaction field "Death" shows the widest count spread between aflibercept and ranibizumab in this extract (4,070-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect aflibercept ranibizumab
Death 7,853 3,783
Visual Impairment 2,013 1,623
Blindness 1,459 1,036
Endophthalmitis 1,372 727
Visual Acuity Reduced 1,244 2,888
Eye Pain 1,181 954
Vision Blurred 1,161 1,029
Blindness Unilateral 1,068 -

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

aflibercept peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Anti-VEGF (Ophthalmic Injection): 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside aflibercept?
This registry lists 1 Anti-VEGF (Ophthalmic Injection) medication records beside aflibercept, including ranibizumab. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide Anti-VEGF (Ophthalmic Injection) peer set (1 records)

aflibercept (Eylea) sits in a wide Anti-VEGF (Ophthalmic Injection) peer set (1 of 1 class peers shown). Labeled indication field for aflibercept: AHZANTIVE treats wet age-related macular degeneration (AMD).

Top FAERS reaction fields for aflibercept total 19,349 reports across 10 reactions, set beside ranibizumab. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full aflibercept profile →

Field note for aflibercept: see also the generic vs brand label guide when reading Eylea SPL strings.